April 9, 2018 04:55 PM EDT
People
Peer Review

Top As­traZeneca I/O vet Robert Ian­none jumps to Im­munomedics as R&D chief as BLA looms

John Carroll

Editor & Founder

Less than a year af­ter the ac­tivist in­vestors at ven­Bio crashed a $2 bil­lion col­lab­o­ra­tion deal with Seat­tle Ge­net­ics on the lead drug at Im­munomedics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times